BIIB
BiogenยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
BIIB Profile
Biogen Inc.
One of the world's first global biotech companies and develops treatments for neurodegenerative, autoimmune and heatologic disorders
225 Binney Street, Cambridge, MA 02142
Manufacture and sale of medicines for the treatment of multiple sclerosis
Biogen Inc., founded in California in 1985 as IDEC Pharmaceuticals, Inc., was re-registered as a Delaware corporation in 1997. In 2003, Biogen, Inc., was acquired and the company name was changed to Biogen Idec Inc. The Company is a global biopharmaceutical company focused on discovering, developing and delivering global innovative therapies for patients with severe neurological and neurodegenerative diseases and related therapeutic adjacent patients. The company's core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular diseases, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. The company is also focused on discovering, developing and delivering global innovative therapies in emerging growth areas such as immunology, neurocognitive disorders, acute neurology and pain.
